An antisense oligonucleotide chain and its method and application for silencing the xanthine dehydrogenase gene in tea plants
By binding a specific sequence of antisense oligonucleotide chain (CsXDH1-asODN) to the xanthine dehydrogenase gene (CsXDH1) in tea, the research problem of xanthine dehydrogenase gene in tea was solved, and the effective regulation of purine alkaloid metabolism in tea was achieved, avoiding the impact on other enzymes.
Patent Information
- Application Number
- CN202310355549.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-04-04
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2043-04-04
AI Technical Summary
Research on xanthine dehydrogenase genes in tea plants is difficult to effectively silence using transgenic technology, as this affects purine alkaloid metabolism. Existing inhibitors, such as allopurinol, affect the activity of other enzymes.
The antisense oligonucleotide chain with a specific sequence (CsXDH1-asODN) was used to specifically bind to the xanthine dehydrogenase gene (CsXDH1) of tea plant, and gene silencing was achieved by incubation with sucrose solution, thereby interfering with purine alkaloid metabolism.
It specifically inhibits xanthine dehydrogenase activity, increases the content of xanthine and caffeine in tea, reduces the content of theobromine, and avoids affecting other enzymes.
Smart Images

Figure CN116606853B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of oligonucleotide application technology, and relates to an antisense oligonucleotide chain and its method and application for silencing the xanthine dehydrogenase gene of tea plants. Background Technology
[0002] Xanthine dehydrogenase catalyzes the continuous oxidation of hypoxanthine to xanthine and xanthine to uric acid in plants, and is a key enzyme regulating the catabolism of purine alkaloids. Caffeine, theobromine, and other purine alkaloids are important secondary metabolites in tea, contributing to the energizing, fatigue-relieving, and anti-inflammatory effects of tea beverages. The metabolic mechanism of purine alkaloids in tea has long been a research focus. Allopurinol, an isomer of hypoxanthine, has been used in some studies on caffeine metabolism in tea by competitively inhibiting xanthine dehydrogenase activity. However, due to its structural similarity to purine compounds, allopurinol and its metabolites inhibit other enzymes involved in purine and pyrimidine metabolism, potentially affecting the effectiveness of its applications.
[0003] Antisense oligonucleotide chains can specifically bind to target gene sequences in plants via the "glycan pathway" to inhibit gene expression. Currently, antisense oligonucleotide silencing technology has been widely used in numerous plant gene function studies. Especially for woody plants, the difficulty of transgenic research or their long growth cycles limits the progress of reverse genetics research, while antisense oligonucleotide chains can achieve silencing effects in a short period. Tea trees are perennial woody plants with lifespans ranging from several decades to hundreds of years, and the difficulty in applying transgenic technology remains a bottleneck in their research. Antisense oligonucleotide silencing methods have been used in several studies on tea trees, and this technology has been proven effective in silencing target genes. Summary of the Invention
[0004] In view of this, the purpose of this invention is to provide an antisense oligonucleotide chain and technical method for silencing the expression of xanthine dehydrogenase gene in tea plants. The antisense oligonucleotide chain and technical method provided by this invention can be used for the study of purine alkaloid metabolism in tea plants.
[0005] To achieve the above objectives, the present invention provides the following technical solution:
[0006] 1. An antisense oligonucleotide chain, the nucleotide sequence of which is shown in SEQ ID NO.1.
[0007] 2. Application of the above-mentioned antisense oligonucleotide chains in silencing the xanthine dehydrogenase gene (CsXDH1) in tea trees or interfering with purine alkaloid metabolism.
[0008] 3. A method for silencing the expression of the xanthine dehydrogenase gene (CsXDH1) in tea plants or interfering with the metabolism of purine alkaloids using the above-mentioned antisense oligonucleotide chain, wherein the method specifically comprises: dissolving the antisense oligonucleotide chain (CsXDH1-asODN) in a sucrose solution to a final concentration of 10-100 μM, wherein the concentration of the sucrose solution is 10-100 μM; and incubating the tea plant shoots to be treated in the above solution for 1-4 days to achieve silencing the xanthine dehydrogenase gene (CsXDH1) in the tea plant shoots or interfering with the metabolism of purine alkaloids.
[0009] Preferably, the tea tree shoots are single buds, one bud and one leaf, one bud and two leaves, or leaf tissue.
[0010] The beneficial effects of this invention are as follows: This invention discloses an antisense oligonucleotide chain, the nucleotide sequence of which is shown in SEQ ID NO.1. This chain silences the xanthine dehydrogenase gene (CsXDH1) in tea plants by specifically binding to it. Compared to using allopurinol to silence the activity of xanthine dehydrogenase in tea plants (allopurinol has a similar structure to purine compounds, and allopurinol and its metabolites inhibit other enzymes involved in purine alkaloid metabolism, potentially affecting the application effect), the antisense oligonucleotide chain disclosed in this invention can specifically act on the xanthine dehydrogenase gene (CsXDH1), thereby reducing the activity of xanthine dehydrogenase.
[0011] Other advantages, objectives, and features of the invention will be set forth in part in the description which follows, and in part will be apparent to those skilled in the art from the following examination, or may be learned from practice of the invention. The objectives and other advantages of the invention can be realized and obtained through the following description. Attached Figure Description
[0012] To make the objectives, technical solutions, and advantages of the present invention clearer, the preferred embodiments of the present invention will be described in detail below with reference to the accompanying drawings, wherein:
[0013] Figure 1 Results of the antisense oligonucleotide chain (CsXDH1-asODN) silencing test;
[0014] Figure 2The effects of silencing the antisense oligonucleotide chain (CsXDH1-asODN) on the content of different substances are shown in Figure A, where the effect of silencing the xanthine dehydrogenase gene (CsXDH1) with the antisense oligonucleotide chain (CsXDH1-asODN) on xanthine content is shown in Figure B, where the effect of silencing the xanthine dehydrogenase gene (CsXDH1) with the antisense oligonucleotide chain (CsXDH1-asODN) on caffeine content is shown in Figure C, and where the effect of silencing the xanthine dehydrogenase gene (CsXDH1) with the antisense oligonucleotide chain (CsXDH1-asODN) on theobromine content is shown in Figure C. Detailed Implementation
[0015] The following specific examples illustrate the implementation of the present invention. Those skilled in the art can easily understand other advantages and effects of the present invention from the content disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and various details in this specification can be modified or changed based on different viewpoints and applications without departing from the spirit of the present invention. It should be noted that the illustrations provided in the following embodiments are only schematic representations of the basic concept of the present invention. Unless otherwise specified, the following embodiments and features can be combined with each other.
[0016] Example 1
[0017] The application of an antisense oligonucleotide chain to silence the expression of the tea xanthine dehydrogenase gene (CsXDH1) is as follows:
[0018] One bud and one leaf of tea shoots were taken as samples for treatment and placed in centrifuge tubes of the experimental group (condition: antisense oligonucleotide chain (CsXDH1-asODN) dissolved in 40 μM sucrose solution, making the CsXDH1-asODN concentration 30 μM) and the control group (condition: 40 μM sucrose solution) for 3 days. Ten replicates were set for each group. The ambient temperature was maintained at 23±1℃; the humidity was approximately 70%; and a visible full-spectrum LED light source was used to simulate a 16-hour day (light intensity of 240 μmol·m⁻¹). -2 ·s -1 After incubation for 8 hours at night, the samples from the experimental group (samples treated with antisense oligonucleotide chains (CsXDH1-asODN) and sucrose) and the samples from the control group (samples treated with sucrose) were rapidly frozen in liquid nitrogen and stored at -80°C for molecular detection.
[0019] The conditions for the molecular detection process are as follows: (1) Total RNA was extracted from the processed samples using the Quick RNA Isolation Kit (Huayueyang, Beijing, China); (2) Goldenstar was used to detect RNA. TMThe RT6 cDNA Synthesis Kit (Qingke, Beijing, China) reverse transcribed the total RNA of each sample into cDNA for real-time quantitative PCR (qRT-PCR) gene expression experiments; (3) The CsTIP41 gene was used as an internal control for light treatment (its primer sequences include upstream CsTIP41-J-F1 (tggagttggaagtggacgagaccga) and downstream CsTIP41-J-R1 (ctctggaaagtgggatgtttgaagc)), and the detection primer sequences for the xanthine dehydrogenase gene (CsXDH1) include upstream CsXDH1-J-F1 (cagcggctctggaatgaactgaag) and downstream CsXDH1-J-R1 (aaccttgccccatctcaacaccc). All the above sequences were designed using Primer Premier 5.0 software, and the qRT-PCR experiment was performed on a CFX96. TM The experiments were performed on a Real-Time System (Bio-Rayet, California, USA), and the fluorescent reagents were obtained using MonAmp. TM ChemoHS qPCR Mix (MonaBio, Jiangsu, China). Reagent ratio: MonAmp TM ChemoHS qPCR Mix 10 μL; forward primer (10 μM) 0.4 μL; reverse primer (10 μM) 0.4 μL; cDNA (50 ng / μL) 2 μL; Nuclease-Free Water 7.2 μL; total reaction volume 20 μL, each sample repeated three times. The amplification program was: 95℃ for 10 min; 95℃ for 10 s; 60℃ for 30 s, 40 cycles. 2 -ΔΔCt The method calculates the relative expression level of genes.
[0020] Example 2
[0021] The application of a method that silences the expression of the xanthine dehydrogenase-encoding gene (CsXDH1) in tea plants using an antisense oligonucleotide chain affects the content of xanthine, caffeine, and theobromine, as detailed below:
[0022] The experimental group samples (samples treated with antisense oligonucleotide chains (CsXDH1-asODN) and sucrose) obtained in Example 1 and the control group samples (samples treated with sucrose) were fixed by microwave for 2 min, then thoroughly dried in an oven at 60°C, ground, passed through a 30-mesh sieve, and stored in a refrigerator at 4°C for biochemical detection.
[0023] Biochemical detection method: Purine alkaloids were extracted from tea samples in both the experimental and control groups using an extraction method. 0.2 g (accurate to 0.0001 g) of sample was weighed into a 10 mL centrifuge tube, and 5 mL of preheated ultrapure water (70℃) was added. The tube was shaken well to fully wet the sample. The sample was then extracted in a 70℃ water bath for 10 min (stirring every 5 min). After extraction, the tube was cooled to room temperature and centrifuged at 3500 rpm. The supernatant was transferred to a 10 mL volumetric flask. The residue was extracted again with 4 mL of ultrapure water, and the above steps were repeated. The extracts were combined and brought to the mark, then shaken well to obtain the sample extract. The sample extract was filtered through a 0.22 μm membrane and then loaded onto a high-performance liquid chromatograph (HPLC) 1220 Infinity II LC (Agilent Technologies, California, USA) for substance detection. Caffeine and theobromine standards were purchased from Feiyu Biotechnology Co., Ltd. (Jiangsu, China), and xanthine standards were purchased from Amida Biotechnology Co., Ltd. (Chongqing, China). Acetonitrile and glacial acetic acid were HPLC grade and filtered through a 0.22 μm membrane before use. Chromatographic conditions were as follows: an Agilent ZORBAX SB-C18 column (5 μm, 4.6*250 mm); UV detection wavelength set to 274 nm; mobile phase A: 0.2% glacial acetic acid; mobile phase B: acetonitrile; flow rate: 0.9 mL / min; column oven temperature: 25℃; injection volume: 20 μL. The gradient elution program was as follows: 8–16% mobile phase B, 0–10 min; 16–20% mobile phase B, 10–20 min; 20–8% mobile phase B, 20–25 min; 8% mobile phase B, 25–30 min.
[0024] Preparation method of caffeine, theobromine, and xanthine standard solutions: Accurately weigh caffeine, theobromine, and xanthine standards, dissolve them in acetonitrile, and prepare 1 mg / mL standard stock solutions respectively. Dilute the stock solutions 25 times with ultrapure water to obtain single-standard test solutions of caffeine, theobromine, and xanthine; mix 1 mL of each of the caffeine, theobromine, and xanthine standard stock solutions and dilute to 25 mL with ultrapure water to prepare a mixed standard test solution of caffeine, theobromine, and xanthine. Analyze the mixed standard test solution before the sample extract using the external standard method.
[0025] The nucleotide sequence of the antisense oligonucleotide chain (CsXDH1-asODN) involved in the above embodiments is shown in SEQ ID NO.1, SEQ ID NO.1: aatgtttccctggcaatcaa.
[0026]
[0027] The sequence of the CsTIP41 gene is shown in SEQ ID NO.4, and SEQ ID NO.4: atggagttggaagtggacgagaccgagctcaaagccgccggagctcagcttcttccggaaggacgcgttggactcttcatacatggttgggagatcgagtctcgcaagcgtcccattctcaactctctccacctccaacagtgggagcataagcttcaaacatcccactttccagagatggtttttggggacagttctttggttcttaaacatgtcagtagtggcattaagattcattttaatacatttgatgctctaactgcctggaagcaggaagcattgccaccagttgaagttcctgcagctgcaaaatggaaattcagaagccaacccttccagcaattggattatgactatacctttacaacaccatattgtggaagtcaaacgattgagataaatgaagagcttgcgagaggagcaacctctgaagataacaactgtggtctttattgggaggactgcaaagagcaaattgatttggctgcactggcatcgaaagagcccattctcttctatgatgaggtaatcttgtatgaagatgaattggcggatagtggtgtttcacttttaactgtaaaagtgagggtaatgccaaactcttggtttcttctcttgcgtttttggcttagagttgatggggtgcttatgagattgagggacacacgtatgcattgtgtttttgcaaatagtgcaacccccattattcttcgagaaagctgttggagggaagccacatttaaagctttgtctgcaaaaggatacccatctgattctgcggcatataatgatccaagcatcatcagccagaggcttcctatcatcatgcataagtcccaaaagcttaaaatccctggtaacctataa.
[0028] The expression levels of the xanthine dehydrogenase gene (CsXDH1) before and after silencing with the antisense oligonucleotide chain (CsXDH1-asODN) disclosed in this invention were detected using real-time quantitative PCR (qRT-PCR) technology to demonstrate the inhibitory effect. The effects of silencing the xanthine dehydrogenase gene (CsXDH1) with the antisense oligonucleotide chain (CsXDH1-asODN) on the xanthine, caffeine, and theobromine content of tea plants were tested using high-performance liquid chromatography (HPLC). Specifically, after silencing the expression of the xanthine dehydrogenase gene (CsXDH1) in tea leaves using the antisense oligonucleotide chain disclosed in this invention, RNA was extracted from the leaves, reverse transcribed, and then subjected to real-time quantitative PCR (qRT-PCR). After silencing the expression of the xanthine dehydrogenase gene (CsXDH1) in tea leaves using the antisense oligonucleotide chain disclosed in this invention, the leaves were blanched and dried, extracted with ultrapure water, and then detected by HPLC.
[0029] Figure 1 Results of the antisense oligonucleotide chain (CsXDH1-asODN) silencing test; Figure 2 The effects of silencing the antisense oligonucleotide chain (CsXDH1-asODN) on the content of different substances are shown in Figure A, where the effect of silencing the xanthine dehydrogenase gene (CsXDH1) with the antisense oligonucleotide chain (CsXDH1-asODN) on xanthine content is shown in Figure B, where the effect of silencing the xanthine dehydrogenase gene (CsXDH1) with the antisense oligonucleotide chain (CsXDH1-asODN) on caffeine content is shown in Figure C, and where the effect of silencing the xanthine dehydrogenase gene (CsXDH1) with the antisense oligonucleotide chain (CsXDH1-asODN) on theobromine content is shown in Figure C. Figure 1 and Figure 2 The control group consisted of samples treated with sucrose, while the experimental group consisted of samples treated with an antisense oligonucleotide chain (CsXDH1-asODN) and sucrose. Different lowercase letters in the figure indicate statistically significant differences (P < 0.05). Figure 1 It can be seen that after silencing the antisense oligonucleotide chain (CsXDH1-asODN), the relative expression level of the xanthine dehydrogenase gene (CsXDH1) decreased by 44.75%. Figure 2 It can be seen that silencing the antisense oligonucleotide chain (CsXDH1-asODN) increased the xanthine content by 98.95%. Figure 2 A); Caffeine content increased by 11.06% ( Figure 2 B); Theobromine content decreased by 9.4% ( Figure 2 C).
[0030] In summary, this invention discloses an antisense oligonucleotide chain, the nucleotide sequence of which is shown in SEQ ID NO.1. This chain specifically binds to the xanthine dehydrogenase gene (CsXDH1) in tea plants to silence the gene, demonstrating good application results. Existing techniques using allopurinol to reduce xanthine dehydrogenase activity in tea plants can affect other similar enzymes in the purine alkaloid pathway, thus impacting the application effect. However, the antisense oligonucleotide chain disclosed in this invention can specifically act on the xanthine dehydrogenase gene (CsXDH1), thereby reducing xanthine dehydrogenase activity.
[0031] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit it. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the spirit and scope of the present invention, and all such modifications or substitutions should be covered within the scope of the claims of the present invention.
Claims
1. An antisense oligonucleotide chain, characterized in that, The nucleotide sequence of the antisense oligonucleotide chain is shown as SEQ ID NO.
1.
2. Use of the antisense oligonucleotide chain of claim 1 in silencing the xanthine dehydrogenase gene of Camellia sinensis or interfering with the metabolism of purine alkaloids.
3. A method of silencing a tea theophylline dehydrogenase gene or interfering with purine alkaloid metabolism using the antisense oligonucleotide of claim 1, wherein The method is specifically: dissolving the antisense oligonucleotide chain in a sucrose solution to make the final concentration of the antisense oligonucleotide chain 10-100 μM, wherein the concentration of the sucrose solution is 10-100 μM, and incubating the Camellia sinensis tender shoots to be treated in the above solution for 1-4 d, so as to realize silencing of the xanthine dehydrogenase gene of the Camellia sinensis tender shoots or interference with the metabolism of purine alkaloids.
4. The method of claim 3, wherein, The Camellia sinensis tender shoots are single bud, one bud one leaf, one bud two leaves or leaf tissue.
